Evidence map›Paper›PMID 36531648›Full record

ArticleThe World Allergy Organization journal2022

The impact of home treatment and self-administration of omalizumab on chronic urticaria.

Anne Christine Wiuff, Malthe Alexander Knudsgaard Wiis, Sofine Heilskov, Anne Sofie Frølunde, Jennifer Astrup Sørensen, Mette Deleuran, Simon Francis Thomsen, Christian Vestergaard

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Anne Christine WiuffDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Malthe Alexander Knudsgaard WiisDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Sofine HeilskovDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Anne Sofie FrølundeDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Jennifer Astrup SørensenDepartment of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
Mette DeleuranDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Simon Francis ThomsenDepartment of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
Christian VestergaardDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Aarhus University Hospital · DKBispebjerg Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients suffering from Chronic Spontaneous Urticaria (CSU) may be recalcitrant to treatment with high dose second-generation antihistamines. These patients are, according to international guidelines, eligible to treatment with omalizumab. Treatment with omalizumab has proven to be very effective for this group of patients. Until 2018, when the self-administration of omalizumab was approved, patients have had to visit an outpatient clinic to receive the treatment. Methods: In this study we performed a survey among 75 CSU patients who had changed their treatment from administration at an outpatient clinic to self-administration at home. Results: None of the patients experienced decreased effect of the treatment with omalizumab, whereas 41.4% reported improved effect of the treatment during self-administration.The most common reported benefits for the patients were decreased travel time and the ability to choose dosing time at the day of treatment, whereas the most reported concern was fear of performing the injection. Conclusions: Patients are very content with self-administration of omalizumab. There has been no decreased effect of the treatment, and as discussed in this paper, there might be other societal benefits from self-administration. Thus, self-administration at home of omalizumab should be standard of care when using this treatment.

Indexed as

Chronic spontaneous urticariaHome-treatmentOmalizumabPatient satisfactionSelf-administration

Identifiers

PMID36531648
PMCPMC9731880
OpenAlexW4310800984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.